GlassScriptPhysician profile
Michael C Strickland
NPI 1740234624
$895.31
in general payments reported to CMS, 2019-2025
19 companies · $232 in 2025
The $232 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $60.60 · 2021: $69.80 · 2022: $118 · 2023: $126 · 2024: $182 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $122.74 | 2024-2025 | |
| Corium, LLC | $94.99 | 2022-2025 | Azstarys |
| Genentech USA, INC. | $80.92 | 2019-2021 | |
| Novo Nordisk INC | $80.03 | 2020-2022 | |
| Abbott Laboratories | $73.59 | 2023-2024 | Freestyle Libre 3, Id Now Instrument |
| Pfizer INC. | $73.45 | 2024 | |
| Merck Sharp & Dohme LLC | $61.68 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $45.51 | 2020-2025 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.27 | 2019-2021 | |
| Glaxosmithkline, LLC. | $38.34 | 2023 | Bexsero, Shingrix, Pediarix |
| Sanofi Pasteur INC. | $36.13 | 2023-2025 | |
| Cranial Technologies, INC | $21.92 | 2025 | Doc Band |
| Acadia Pharmaceuticals INC | $20.78 | 2025 | Daybue |
| Eisai INC. | $18.60 | 2021 | |
| Amarin Pharma, INC. | $18.42 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.12 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.65 | 2023 | Kristalose |
| Astrazeneca Pharmaceuticals LP | $14.80 | 2024 | Flumist Quadrivalent |
| Shire North American Group INC | $14.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Strickland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.